Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 950 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

FDA to review NeurogesX sNDA for Qutenza

Qutenza (capsaicin) 8% patch is a localised dermal delivery system comprising prescription strength capsaicin. Qutenza is currently FDA approved as a 60-minute application for the management of neuropathic

Horizon Pharma third quarter net loss widens

Revenues decreased by $0.4m, compared to the same period in 2010, primarily due to the timing of purchases by the company’s distribution partners. Research and development (R&D) expenses

TETF funds Leonardo drug delivery technology

The company’s multi-stage drug delivery technology is based on micron-sized particles of porous silicon particles which protect their payload from several key defenses used by the body and

Concert presents CTP-499 drug Phase1 study data

CTP-499 is an analog of 1-((S)-5-hydroxyhexyl)-3,7-dimethylxanthine (HDX), an active metabolite of pentoxifylline and has a pleiotropic mechanism of action including angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor